Table VII.
Univariate analysis of baseline and clinical characteristics as prognostic factors for survival time in oxaliplatin-based chemotherapy.
| Clinicopathological characteristic | HR | 95% CI | P-value |
|---|---|---|---|
| Age | N.S. | ||
| <60 | 1 | ||
| ≥60 | 1.19 | 0.38–3.65 | |
| Sex | N.S. | ||
| Male | 1 | ||
| Female | 0.44 | 0.09–1.50 | |
| Histological type | N.S. | ||
| Differentiated adenocarcinoma | 1 | ||
| Undifferentiated adenocarcinoma | 0.81 | 0.26–3.08 | |
| Performance status | 0.0256 | ||
| 0 | 1 | ||
| 1/2 | 5.61 | 1.09–25.8 | |
| Primary tumor location | N.S. | ||
| Duodenum | 1 | ||
| Jejunum, Ileum | 1.09 | 0.28–7.20 | |
| CEA (ng/ml) | N.S. | ||
| ≤5 | 1 | ||
| >5 | 1.17 | 0.38–3.98 | |
| CA19-9 (ng/ml) | N.S. | ||
| ≤40 | 1 | ||
| >40 | 0.97 | 0.29–4.34 | |
| Liver metastasis | N.S. | ||
| Absent | 1 | ||
| Present | 1.07 | 0.29–3.24 | |
| Lung metastasis | N.S. | ||
| Absent | 1 | ||
| Present | 1.38 | 0.21–5.32 | |
| Resection of primary tumor | N.S. | ||
| No | 1 | ||
| Yes | 0.40 | 0.12–1.27 | |
| Bevacizumab treatment | 0.0121 | ||
| No | 1 | ||
| Yes | 0.16 | 0.02–0.69 |
HR, hazard ratio; CI, confidence interval; N.S., not significant; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.